NGVB Logo


Report Summary

Direct Comparative Analysis of rAAV1 and rAAV5 Pseudotyped Vectors Using Aerosol Delivery of Firefly and Renila Luciferase Reporters Co-delivered to the Lungs of Chimpanzees


Study Summary

Overall Study Design 
The selection of the most efficient rAAV capsid serotype for airway gene therapy of cystic fibrosis CF has been challenging 
due to cross-specific differences in tropism between humans and animal models Additionally species-specific differences 
in the immune response profile to various rAAV serotypes can also greatly impact the outcome of clinical trials Investigators 
postulated that the use of chimpanzees which are the closest surviving genetic relative to humans could be the most 
predictive model for selection of a rAAV serotype best suited for human trials in CF patients 

More details on this study are available to registered users. To get access, you need to:
  1. Have an NGVB account: click here to create one
  2. Send an e-mail to the NGVB Biorepository Manager to request access:

    Lorraine Matheson
    NGVB Biorepository Manager
    317-274-4519
    Please enable JavaScript in your browser to see the e-mail address.